NCT04922723View on ClinicalTrials.gov

Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Glioblastoma

Interventions

DRUG

Daratumumab

Daratumumab will be administered by IV infusion to subjects in combination with current therapeutic strategies of surgical resection followed by a course of Temozolomide and radiation therapy.

Trial Locations (1)

26506

West Virginia University Cancer Institute Mary Babb Randolph Cancer Center, Morgantown

All Listed Sponsors

lead

West Virginia University

OTHER